오큘러 테라퓨틱스(OCUL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $9.99 (-1.48%), 시가총액 $1.76B, 52주 최저~최고 $6.88 ~ $16.11.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phas
오큘러 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오큘러 테라퓨틱스의 현재 주가는 $9.99 (-1.48%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오큘러 테라퓨틱스의 시가총액은 약 $1.76B입니다.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-base